<div id="readability-page-1"><p>In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, with a price target of <span id="expert-recommendation-target">$276.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Jason Gerberry has given his Buy rating due to a combination of factors related to Auvelity’s expanding commercial opportunity and the stock’s valuation. He highlights that management’s new $8 billion peak sales ambition for Auvelity, supported by the recent approval in Alzheimer’s disease agitation and a favorable label, is not fully reflected in the current share price, even versus more conservative consensus peak estimates. </p> <p>He also points to the upcoming Alzheimer’s agitation launch, the enlarged 630-person sales force promoting both depression and Alzheimer’s indications, and the proven benefits of indication stacking in CNS drugs as key growth drivers that can unlock substantial upside. Additionally, he notes robust early traction in major depressive disorder, rising peak MDD sales assumptions, and a strengthened longer-term pipeline, all of which underpin his reiterated Buy rating and increased price objective of $276 per share.</p> <p>According to TipRanks, Gerberry is a 5-star analyst with an average return of <span>18.9%</span> and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and BioMarin Pharmaceutical.</p> <p>In another report released yesterday, Needham also assigned a Buy rating to the stock with a $267.00 price target.</p></div>

AXSM

<p>Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, raising the price target to $276. He cites Auvelity’s expanding commercial opportunity in Alzheimer’s disease agitation and management’s $8 billion peak sales ambition as key factors. The upcoming launch and a strengthened sales force are expected to drive growth. Needham also assigned a Buy rating with a $267 target. Gerberry is a 5-star analyst with an 18.9% average return and a 61.32% success rate.</p>

- In a report released yesterday, Jason Gerberry of Bank of America Securities reiterated a 'Buy' rating on Axsome Therapeutics with a target price of $276.00.  
- His rating is based on various factors related to Auvelity's expansion opportunities, projecting peak sales of $8 billion, which he believes is not fully reflected in the current stock price.  
- The report highlights key growth drivers, including a strong pipeline in major depressive disorder and the upcoming Alzheimer's agitation treatment.

Tip Ranks

Axsome Therap

Bank of America

Ionis Pharma

Alkermes

BioMarin Pharma

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target